+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05916313

Testing Different Doses of BI 764532 by Intravenous Infusion in Adults with DLL3-Positive Glioma

Led by Boehringer Ingelheim · Updated on 2026-10-27

20

Participants Needed

12

Research Sites

7 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with a brain tumour that tests positive for the tumour marker delta-like 3 DLL3, focusing on those whose previous treatments were not successful. This trial aims to find the highest dose of BI 764532, an antibody-like molecule that may help the immune system fight cancer by linking cancer cells and immune T-cells. The study is a phase 1, open-label, dose escalation trial sponsored by Boehringer Ingelheim. Participants receive BI 764532 through intravenous infusions at the start of treatment. If the treatment shows benefit and is well tolerated, it continues, with the number of visits depending on individual response and tolerance. Initial visits include close monitoring for safety. The study does not involve placebo or comparison groups and focuses on escalating doses to determine the maximum tolerated dose. During the study, participants attend regular visits where doctors monitor safety, record any side effects, and check overall health. The main outcome measured is the occurrence of dose-limiting toxicities during the first four weeks of treatment, with secondary measures extending up to 26 months. The study duration and visits vary depending on how participants respond and tolerate the treatment, ensuring careful assessment throughout.

CONDITIONS

Brief Title

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here